



PTO/SB/08a (05-07)

Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		09914279	
	Filing Date		2002-01-09	
	First Named Inventor	O'Hagan et al.		
	Art Unit	1615		
	Examiner Name	Carlos A. Azpuru		
	Attorney Docket Number	PP01573.101		

### U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5733877		1998-03-31	Sato et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

### U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	9014837	WO	A1	1990-12-13	Chiron Corporation		<input type="checkbox"/>
	2	9833932	WO	A1	1998-08-06	Korea Institute of Science and Technology		<input type="checkbox"/>
	3	9911241	WO	A1	1999-03-11	Smithkline Beecham Biologicals S.A.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09914279
Filing Date	2002-01-09
First Named Inventor	O'Hagan et al.
Art Unit	1615
Examiner Name	Carlos A. Azpuru
Attorney Docket Number	PP01573.101

4	9912565	WO	A1	1999-03-18	Smithkline Beecham Biologicals S.A.	<input type="checkbox"/>
5	0006120	WO	A1	2000-12-10	Korea Institute of Science and Technology	<input type="checkbox"/>
6	0050006	WO	A2	2000-08-31	Chiron Corporation	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	M. Singh et al., "A Comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2", Vaccine, (1998), Vol. 16, No. 19, Pgs. 1822-1826.	<input type="checkbox"/>
	2	A.C. Allison et al., "An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity", Journal of Immunological Methods, (1986), Vol. 95, Pgs. 157-168.	<input type="checkbox"/>
	3	Instruction Manual "CAT ELISA", Version March 2005, 22 pages	<input type="checkbox"/>
	4	S.W. Yi et al., "Cationic Lipid Emulsion; A Novel, Non-Viral, and Non-Liposomal Gene Delivery System", Proceed. Int'l. Symp. Control. Rel. Bioact. Mater. (1997), Vol. 24, Pgs. 653-654.	<input type="checkbox"/>
	5	B.D. Freimark et al., "Cationic Lipids Enhance Cytokine and Cell Influx Levels in the Lung Following Administration of Plasmid: Cationic Lipid Complexes", The Journal of Immunology, (1998), Vol. 160, Pgs., 4580-4586.	<input type="checkbox"/>
	6	G. Ott et al., "Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines", Vaccine Design, (1995), Pgs. 277-295.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		09914279
Filing Date		2002-01-09
First Named Inventor	O'Hagan et al.	
Art Unit	1615	
Examiner Name	Carlos A. Azpuru	
Attorney Docket Number	PP01573.101	

7	D.T. O'Hagan et al., "Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines", Advanced Drug Delivery Reviews, (1998), Vol. 32, Pgs. 225-246.	<input type="checkbox"/>
8	D.T. O'Hagan et al., "Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles", Molecular Medicine Today, February 1997, Pgs. 69-75.	<input type="checkbox"/>
9	M. Singh et al., "The preparation and characterization of polymeric antigen delivery systems for oral administration", Advanced Drug Delivery Reviews, Vol. 34, (1998), Pgs. 285-304.	<input type="checkbox"/>
10	R.T. Lostritto et al., "Theoretical Considerations of Drug Release from Submicron Oil in Water Emulsions", Journal of Parenteral Science & Technology, November-December 1987, Vol. 41, No. 6, Pgs. 214-219.	<input type="checkbox"/>
11	Summons to Attend Oral Proceedings dated October 26, 2007; cited in the counterpart European Patent No. EP1156781B1	<input type="checkbox"/>
12	Opponent GlaxoSmithKline's Submission Before Oral Proceeding Filed on December 14, 2007, cited in the counterpart European Patent No. EP1156781B1	<input type="checkbox"/>
13	Opponent GlaxoSmithKline's Further Submission Before Oral Proceeding Filed on February 19, 2008, cited in the counterpart European Patent No. EP1156781B1	<input type="checkbox"/>
14	Notice of Appeal filed by Opponent GlaxoSmithKline on June 6, 2008; cited in the counterpart European Patent No. EP1156781B1	<input type="checkbox"/>
15	Statement of Grounds of Appeal filed by Opponent GlaxoSmithKline on July 25, 2008; cited in the counterpart European Patent No. EP1156781B1	<input type="checkbox"/>
16	Opponent GlaxoSmithKline's Reply to Proprietor's Grounds of Appeal and cited references Filed on December 19, 2008, cited in the counterpart European Patent No. EP1156781B1	<input type="checkbox"/>
17	Copy of Certified Provisional Application No. 60/121,858	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09914279
Filing Date	2002-01-09
First Named Inventor	O'Hagan et al.
Art Unit	1615
Examiner Name	Carlos A. Azpuru
Attorney Docket Number	PP01573.101

18	Copy of Certified Provisional Application No. 60/146,391	<input type="checkbox"/>
----	--	--------------------------

19	Copy of Certified Provisional Application No. 60/161,997	<input type="checkbox"/>
----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.